CXCL16 further remodels the TME by reprogramming TAMs, Cancer-Associated Fibroblasts (CAFs), and Myeloid-Derived Suppressor Cells (MDSCs), highlighting its therapeutic duality (Korbecki et al., 2021). This evidence concerns the gene CXCL16 and cancer.